Metagenomi Therapeutics, Inc.
MGX evidence brief
What we can confirm
- BioSniper Score:
- 6.5 / 10
- Market Cap:
- $43.8M
What it means
What to watch
Prepared research question
What matters most for MGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MGX
Metagenomi Therapeutics, Inc. (MGX) is a publicly traded gene-editing company focused on developing in vivo genome integration therapies, with its lead candidate MGX-001 targeting hemophilia A and a cash runway projected through late 2027.
Key risk: Cash burn rate
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$43.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Metagenomi Therapeutics, Inc. (MGX) is a publicly traded gene-editing company focused on developing in vivo genome integration therapies, with its lead candidate MGX-001 targeting hemophilia A and a cash runway projected through late 2027.
- Completed a pre-IND meeting for lead candidate MGX-001 (hemophilia A) and remains on track for global regulatory submission including IND in 4Q 2026 [news · published 2026-03-06]
- Cash, cash equivalents and available-for-sale marketable securities were $120.7 million as of June 30, 2026, with runway anticipated to support operations through 4Q 2027 [sec_mda · as of 2026-08-10]
- Net loss of $27.5 million for the period ended June 30, 2026 [latest reported financials (as of 2026-06-30)]
- Shareholders' equity stood at $112.6 million as of June 30, 2026 [latest reported financials (as of 2026-06-30)]
- Corporate name changed to Metagenomi Therapeutics, Inc. to reflect strategic evolution toward later-stage preclinical assets [news · published 2026-01-12]
What works
- Lead candidate MGX-001 demonstrated curative FVIII activity in non-human primates, supporting a planned IND submission in 4Q 2026 [news · published 2026-03-06]
- Cash runway is estimated through 4Q 2027, providing approximately 18 months of operating capital from mid-2026 [sec_mda · as of 2026-08-10]
- Collaboration with Ionis Pharmaceuticals covers four cardiometabolic targets, including TTR and AGT, leveraging Metagenomi's genome editing technologies [sec_mda · as of 2025-11-12]
What to weigh
- Cash reserves have declined from $248.3 million (Dec 2024) to $120.7 million (Jun 2026), a burn rate that may pressure the company to raise additional capital before 4Q 2027 [sec_mda · as of 2026-08-10]
- Net loss of $27.5 million for the six months ended June 30, 2026 indicates ongoing operating losses with no approved products generating revenue [latest reported financials (as of 2026-06-30)]
- MGX-001 is still in preclinical stage; regulatory submissions are not expected until late 2026, with clinical trials likely starting in 2027, meaning no near-term product revenue [sec_mda · as of 2025-11-12]
From the filings
Quoted directly from source documents.
MGX-001 preclinical data showed curative FVIII activity in NHPs and IND on track for 4Q 2026
“Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026”
News · March 6, 2026
Cash position as of June 30, 2026 was $120.7 million
“As of June 30, 2026, we had $120.7 million in cash, cash equivalents and available-for-sale marketable securities.”
SEC MD&A · August 10, 2026
Corporate name change to Metagenomi Therapeutics, Inc.
“Announced corporate name change to Metagenomi Therapeutics, Inc. to reflect Company’s strategic evolution”
News · March 6, 2026
Risks & what to watch (3)›
Key risks
- Cash burn rate — Cash declined from $248.3M (Dec 2024) to $120.7M (Jun 2026); runway only through 4Q 2027 [sec_mda · as of 2026-08-10]
- No approved products — MGX-001 is preclinical; no revenue from product sales; net loss of $27.5M in H1 2026 [latest reported financials (as of 2026-06-30)]
- Regulatory uncertainty — IND submission for MGX-001 not expected until 4Q 2026; clinical trials may start in 2027 [sec_mda · as of 2025-11-12]
What to watch
- IND/CTA submission for MGX-001 expected in 4Q 2026 [news · published 2026-03-06]
- Cash runway updates; current estimate through 4Q 2027 [sec_mda · as of 2026-08-10]
- Progress of Ionis collaboration on cardiometabolic targets (TTR, AGT) [sec_mda · as of 2025-11-12]
- Any additional financing or partnership announcements given declining cash reserves
Sources: News · SEC MD&A · Generated September 27, 2026 · How we verify sources →
Run Metagenomi Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Metagenomi Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.54 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 6 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
48
Total value held
$8.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,057,944 | $1.4M |
| renaissance technologies llc | 787,900 | $1.1M |
| catalio capital management, lp | 528,993 | $709K |
| peapod lane capital llc | 516,761 | $683K |
| two sigma investments, lp | 496,767 | $666K |
| bridgeway capital management, llc | 395,800 | $530K |
| jacobs levy equity management, inc | 382,153 | $512K |
| geode capital management, llc | 358,200 | $480K |
| pura vida investments, llc | 264,391 | $354K |
| blackrock, inc. | 230,134 | $308K |
Showing top 10 of 48 institutional holders of Metagenomi Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 7.9%
- Days to cover
- 8.2
- Shares short
- 2,167,525
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MGX short interestFrequently asked questions
What is the AI investment thesis for Metagenomi Therapeutics, Inc.?
Metagenomi Therapeutics, Inc. (MGX) is a publicly traded gene-editing company focused on developing in vivo genome integration therapies, with its lead candidate MGX-001 targeting hemophilia A and a cash runway projected through late 2027.
Who is the CEO of Metagenomi Therapeutics, Inc.?
Dr. Jian Irish M.B.A., Ph.D. is the chief executive officer of Metagenomi Therapeutics, Inc. (MGX).
Where is Metagenomi Therapeutics, Inc. headquartered?
Metagenomi Therapeutics, Inc. (MGX) is headquartered in EmeryVille, CA, United States.
What therapeutic areas does Metagenomi Therapeutics, Inc. focus on?
Metagenomi Therapeutics, Inc. develops therapies across Rare Disease, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.